It was reported that BRD2/4 and ATAD2, both co-activators of AR, mediate increased chromatin accessibility and AR association with chromatin in CRPC compared with benign prostate hyperplasia, potentially contributing to enzalutamide resistance (143). This evidence concerns the gene AR and benign prostatic hyperplasia.